DENOSUMAB-MOBZ

RANKL Inhibitor

Brand names: Boncresa

Subcutaneous

Mechanism of Action

12.1 Mechanism of Action Denosumab productsbinds to RANKL, a transmembrane or soluble protein essential for the formation, function, and survival of osteoclasts, the cells responsible for bone resorption. Denosumab productsprevent RANKL from activating its receptor, RANK, on the surface of osteoclasts and their precursors. Prevention of the RANKL/RANK interaction inhibits osteoclast formation, function, and survival, thereby decreasing bone resorption and increasing bone mass and strength in both cortical and trabecular bone.

Indications

defined as a history of osteoporotic fracture

or multiple risk factors for fracture

or patients who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis

denosumab reduces the incidence of vertebral

nonvertebral

defined as a history of osteoporotic fracture

Contraindications

• facial swelling
• and urticaria [see Warnings and Precautions (5.3) and Adverse Reactions (6.2) ] . Hypocalcemia (4
• 5.1) Pregnancy (4
• 8.1) Known hypersensitivity to denosumab products (4
• 5.3)

FDA Warnings

5 WARNINGS AND PRECAUTIONS Same Active Ingredient: Patients receiving Boncresa should not receive other denosumab products concomitantly
Concomitant use of calcimimetic drugs may also worsen hypocalcemia risk
6) Serious infections including skin infections: May occur, including those leading to hospitalization
1 Severe Hypocalcemia and Mineral Metabolism Changes Denosumab products can cause severe hypocalcemia and fatal cases have been reported

Known Side Effects

0 documented side effects by frequency

No structured side effect data available.

Community Discussions

No community discussions found for DENOSUMAB-MOBZ yet.

Compare With

3 available comparisons

Formulations

Dosage Forms

Tablet

Route

Subcutaneous